T cell, human cord blood unstim.

Cord Blood CD4+ T cells which express the cell surface marker CD45RA are defined as naive and are deficient in their ability to assist in antibody production. Such cells are particularly abundant in human cord blood3. CD4+ T cells are commonly used to produce Th0, Th1 and Th2 T cell populations. The Cord Blood CD4+ T cells are isolated from cord blood mononuclear cells using negative immunomagnetic selection.

Cell Type:
T Cell
Tissue Origin:
blood
Species:
human
Research Area:
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

TheraPEAK® X-VIVO® Media is a high-performing media series providing nutritionally adequate and balanced environments for a variety of hematopoietic cells including: 

  • T Cells
  • CAR-T cells
  • Peripheral blood lymphocytes (PBL)
  • Tumor infiltrating lymphocytes (TIL)
  • Human monocytes and macrophages
  • Lymphokine-activated killer cells (LAK)
  • Hematopoietic stem cells (HSCs)
  • Dendritic cells (DCs) 

Our scalable media are widely cited in scientific publications and proven to reliably work in many cell therapy applications around the world, from research stages to clinical trials to FDA-approved cell therapies. TheraPEAK® Products are manufactured according to GMP standards and can be safely and confidently used in your clinical processes. Our manufacturing sites are FDA registered with an ISO 13485 certified quality management system. 


There are two main versions of this media.

TheraPEAK® X-VIVO® 10 Media are  optimized for slower growing, less mature cells, such as hematopoietic stem cells

TheraPEAK® X-VIVO® 15 Media are most appropriate for rapidly growing cells, specifically cells of the immune system

TheraPEAK® X-VIVO® 10 Media and 15 Media are also available with recombinant transferrin instead of native human transferrin

Please note: X-VIVO™ 20 is currently available as an RUO grade catalog item. 

Storage: 2-8C, protect from light.

Catalog Offerings:

TheraPEAK® X-VIVO® Medium with native transferrin

Cat. No. NA

Cat.CCat. No. EU

Product

Size

BP04-743Q                            

 

           BEBP04-743Q

TheraPEAK® X-VIVO® 10 Medium without gentamicin and phenol red, contains native transferrin

1 L bottle

BP04-744Q

 

BEBP04-744Q

TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains native transferrin

1 L bottle

08-879H

08-879P1

 

BE08-879H

BE08-879P1

TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains native transferrin

5 L bag

1 L bag

TheraPEAK™ X-VIVO™ Medium with recombinant transferrin

Cat. No. NA

Cat. No. EU

Product

Size

N/A

BEBP02-055Q

TheraPEAK® X-VIVO® 10 Medium with L-glutamine, without gentamicin or phenol red, contains recombinant transferrin

1 L bottle

BP02-054Q

BP02-054P1

BEBP02-054Q

BEBP02-054P1

TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains recombinant transferrin

1 L bottle

1 L bag

TheraPEAK® T-VIVO® Cell Culture Medium is a chemically-defined, non-animal origin (NAO) cell culture medium to culture and grow a variety of hematopoietic cells including:
  • T cells: both dd (Gamma Delta) and aß (Alpha Beta) subpopulations
  • CAR-T cells
  • Peripheral blood lymphocytes (PBL)
  • Tumor infiltrating lymphocytes (TIL)
Its novel chemically defined formulation is serum-free and non-animal origin (NAO) to ensure consistency and provide increased process control.  

Unlike other serum-free T-cell culture media, TheraPEAK® T-VIVO®  Cell Culture Medium does not require the addition of human serum (HS) to achieve the desired performance. It does not contain cytokines, antibiotics or phenol red.

Traceability documentation is available including Certificates of Analysis and a Drug Master File. TheraPEAK® T-VIVO® Cell Culture Medium also scale up from preclinical development through to manufacturing.

TheraPEAK® T-VIVO® Cell Culture Medium is available in the following formats/sizes: 

  • 1 L bottle (catalog # BP12-970Q)
  • 1 L bag (catalog # BP08-970Y)

Customization of packaging for specific applications is available upon request. Please contact us for additional information.

All TheraPEAK® Products are produced according to applicable GMP standards and follow the USP/EP guidance for cell and gene therapy raw materials. TheraPEAK® Media Products are produced at FDA registered manufacturing sites under the auspices of ISO 13485 certified Quality Management Systems.









Transfection Information

In case no data are shown for the selected cell type, please take a look at our optimization strategy or contact our Scientific Support Teams to get further guidance on how to easily determine optimal Nucleofection conditions yourself.

Citations (7)

Categories:
Primary Cells and Media, Transfection 
Authors:
Farboud B1, Jarvis E2, Roth TL3, Shin J4, Corn JE4, Marson A5, Meyer BJ1, Patel NH6, Hochstrasser ML7. 
In:
J Vis Exp (2018) 2018: 135 
Categories:
Transfection 
Authors:
Zhang Y, Zhang X, Cheng C, Mu W, Liu X, Li N, Wei X, Liu X, Xia C, Wang H. 
In:
Frontiers in Immunology (2017) 1: 1-9 
Categories:
Transfection 
Authors:
Prabha Chandrasekaran, Victoria Moore, Monica Buckley, Joshua Spurrier, John H. Kehrl, Sundararajan Venkatesan 
In:
PLoS ONE (2014) 9(1): e86998 
Categories:
Primary Cells and Media, Classical Media and Reagents, Serum-free and Speciality Media 
Authors:
Isgro J, Gupta S, Jacek E, Pavri T, Duculan R, Kim M, Kirou KA, Salmon JE, Pernis AB 
In:
Arthritis Rheum (2013) 65(6): 1592-602 
Categories:
Transfection 
Authors:
Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. 
In:
PLoS ONE (2013) 8(5): 64138 
Categories:
Primary Cells and Media 
Authors:
Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, Cermak J 
In:
J Hematol Oncol (2011) 6(4): 1 
Categories:
Primary Cells and Media, Classical Media and Reagents, Serum-free and Speciality Media 
Authors:
Yang D, Chen Q, Chertov O, Oppenheim JJ. 
In:
J Leukoc Biol (2000) 68(1): 9-14 
+ Show All